Affiliation:
1. Division of Infectious Diseases Warren Alpert Medical School of Brown University, Rhode Island Hospital Rhode Island USA
2. Division of Internal Medicine Warren Alpert Medical School of Brown University, Rhode Island Hospital Rhode Island USA
3. Department of Electrical and Computer Engineering National Technical University of Athens Athens Greece
4. Division of Gastroenterology and Hepatology Providence VA Medical Center Providence Rhode Island USA
5. Liver Research Center The Warren Alpert Medical School of Brown University Providence Rhode Island USA
6. Department of Medicine Houston Methodist Hospital Houston Texas USA
Abstract
AbstractNon‐alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease. The association between prior hepatitis B virus (HBV), hepatitis A virus (HAV), hepatitis E virus (HEV) infection and NAFLD remains unclear. We utilized the 2017–2020 National Health and Nutrition Examination Survey (NHANES) and performed multivariable logistic regression analyses to examine the association of prior HBV, HAV and HEV infection with NAFLD, as well as high risk non‐alcoholic steatohepatitis (NASH) and liver fibrosis. Our analysis included 2565 participants with available anti‐HBc serology results, 1480 unvaccinated participants with anti‐HAV results, and 2561 participants with anti‐HEV results. Among participants with NAFLD, the age‐adjusted prevalence of prior HBV, HAV and HEV infection was 3.48%, 32.08% and 7.45%, respectively. Prior infection with HBV, HAV and HEV was not associated with NAFLD (cut‐off 285 dB/m) [aOR: 0.99 (95% CI, 0.77–1.29), 1.29 (95% CI, 0.95–1.75), and 0.94 (95% CI, 0.70–1.27), respectively] or high‐risk NASH [aOR 0.72 (95% CI, 0.45–1.17), 0.92 (95% CI, 0.55–1.52), and 0.89 (95% CI, 0.41–1.94), respectively]. Participants with anti‐HBc and anti‐HAV seropositivity were more likely to have significant fibrosis [aOR: 1.53 (95% CI, 1.05–2.23) and 1.69 (95% CI, 1.16–2.47), respectively]. The odds of significant fibrosis are 53%, and 69% greater for participants with prior history of HBV and HAV infection. Healthcare providers should prioritize vaccination efforts and employ a tailored approach to NAFLD in patients with prior viral hepatitis and especially HBV or HAV infection to limit disease‐related outcomes.
Subject
Virology,Infectious Diseases,Hepatology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献